Accelerate Your
Antibody Discovery Process
Our Beacon® platform is revolutionizing antibody discovery with a function-first approach that maximizes discovery success. From high-throughput screening to rapid lead identification, we empower researchers like you with scalable, customizable solutions across species and challenging targets.
Curious how our technology can impact your antibody discovery research? Contact us today to discuss how we can support your next breakthrough.
Discover how top labs are using the Beacon® platform to overcome antibody discovery challenges and achieve breakthrough results:
Can monoclonal antibodies derived from convalescent COVID-19 patients be used to neutralize SARS-CoV-2 for use as an antibody therapeutic?
Researchers rapidly screened memory B cells from two convalescent patients using the Beacon® platform, recovering 389 recombinant monoclonal antibodies. Among them, 70 were found to fully or partially neutralize SARS-CoV-2.
The Beacon platform significantly expedited the discovery of antibody therapeutic candidates. This study contributed to the development and emergency use authorization of Evusheld™, highlighting how the Beacon system can rapidly identify critical antibodies for therapeutic applications.
James E. Crowe, Jr., MD
Director, Vanderbilt Vaccine Center
Can monoclonal antibodies derived from convalescent COVID-19 patients that are broadly reactive against seven coronavirus variants be used to discover a novel target epitope for future vaccine development?
Researchers used the Beacon platform to rapidly screen memory B cells from 19 convalescent patients, recovering 60 recombinant monoclonal antibodies cross-reactive against three coronaviruses. Of these, six were cross-reactive against seven coronaviruses, all targeting the same highly conserved epitope on the S2 subunit across 34 viral isolates. Additionally, two of these antibodies demonstrated neutralization in a hamster model.
Leveraging the Beacon platform allowed researchers to quickly identify broadly neutralizing antibodies, offering insights into potential vaccine development that could target conserved viral epitopes across multiple coronavirus variants.
Joshua Tan, PhD
Chief, Antibody Biology Unit,
Laboratory of Immunogenetics, NIAID, NIH
Do most antibody-secreting cells (ASCs) meet the standard definition of actively dividing and antibody-secreting plasmablasts?
Researchers used optofluidics to study functional characteristics (IgG secretion and proliferation) of single antibody-secreting cells (ASCs) derived from blood and bone marrow over 7-21 days. They found that most ASCs were no longer dividing, challenging the traditional understanding of circulating plasmablasts.
Optofluidics enables multimodal analysis and functional characterization of cells beyond standard classification techniques by FACS. This study challenges the long-held assumption that most periphery ASCs are “plasmablasts” and instead suggests a need to further understand the signaling and cell cycle kinetics of early-minted ASCs into long-lived plasma cells.
Frances Eun-Hyung Lee, MD
Professor, Department of Medicine,
Emory Vaccine Center
Can the Beacon system be used to overcome challenges to heavy-chain-only antibody (HCAb) discovery?
Researchers used optofluidics and proprietary reagents to isolate and screen antigen-specific B cells derived from immunized alpaca blood for two different antigens.
The Beacon Optofluidic Platform allowed researchers to quickly adapt and screen B cells from novel species, such as alpacas, leading to the discovery of HCAbs. This demonstrates the platform's flexibility and capacity to support antibody discovery from diverse species for both therapeutic and research applications.
Mariya Shapiro, PhD
Director, Upstream Antibody Discovery,
Twist Bioscience
Can monoclonal autoantibodies derived from autoimmune patients be discovered to narrow the mechanism of action responsible for neurologic disease?
Researchers used the Beacon platform’s 50k-cell throughput to rapidly screen memory B cells derived from an autoimmune patient. They recovered five monoclonal antibodies specific for the CD320 transporter (0.02% antigen-specific rate), resulting in discovering a single B cell receptor sequence that blocked transcobalamin-B12 uptake through the CD320 pathway.
The Beacon platform enabled the rapid discovery of autoantibodies that block the CD320 pathway, preventing vitamin B12 uptake. This accelerates our understanding of autoimmune mechanisms and opens new possibilities for therapeutic developments, including anti-idiotypic antibodies and next-generation CAR-T therapies.
Michael Wilson, MD, MAS
Professor, Neurology
UCSF Weill Institute for Neurosciences
Your Antibody Discovery?
Our advanced antibody discovery platform is designed to meet your specific research needs. Whether you’re looking to accelerate screening, optimize lead candidates, or explore complex targets, we’re here to help.
Fill out the form below, and one of our experts will be in touch to discuss how we can support your research goals and answer any questions you may have.
with Limited or Precious Samples